This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Concern has been raised about the cardiovascular safety of cisapride following postmarketing reports of QT-interval prolongation and serious ventricular arrhythmias.¹ As a consequence, the labeling of cisapride has been revised and there have been efforts to inform health care professionals about this.^2-3 Despite these risk management efforts, Janssen Pharmaceutica Inc decided to stop marketing cisapride in the United States in July 2000.⁴ In Europe, the United Kingdom and Germany suspended licensing for the drug while its risks and benefits are being reevaluated by the European Agency for the Evaluation of Medicinal Products. The degree of prescribers' adherence to the warnings and contraindications raised by health authorities remains critical in the evaluation of the overall safety of the drug.⁵

We carried out a cohort study, in the Italian region of Umbria, to evaluate the frequency of overlapping prescription of cisapride and contraindicated drugs and to evaluate the . . . [Full Text of this Article]

Methods



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacogenetics in drug regulation: promise, potential and pitfalls
Shah
Phil Trans R Soc B 2005;360:1617-1638.
ABSTRACT | FULL TEXT